ADCT
Price:
$1.99
Market Cap:
$192.41M
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relap...[Read more]
Industry
Biotechnology
IPO Date
2020-05-18
Stock Exchange
NYSE
Ticker
ADCT
According to ADC Therapeutics SA’s latest financial reports and current stock price. The company's current Enterprise Value is 249.65M. This represents a change of 24.39% compared to the average of 200.70M of the last 4 quarters.
The mean historical Enterprise Value of ADC Therapeutics SA over the last ten years is 952.82M. The current 249.65M Enterprise Value has changed 2.52% with respect to the historical average. Over the past ten years (40 quarters), ADCT's Enterprise Value was at its highest in in the June 2020 quarter at 2.63B. The Enterprise Value was at its lowest in in the September 2023 quarter at -113093608.24.
Average
952.82M
Median
1.32B
Minimum
-143669000.00
Maximum
1.87B
Discovering the peaks and valleys of ADC Therapeutics SA Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 28.48%
Maximum Annual Enterprise Value = 1.87B
Minimum Annual Increase = -1131.72%
Minimum Annual Enterprise Value = -143669000.00
Year | Enterprise Value | Change |
---|---|---|
2023 | -18578804.44 | -120.41% |
2022 | 91.04M | -92.32% |
2021 | 1.19B | -30.12% |
2020 | 1.70B | -9.39% |
2019 | 1.87B | 28.48% |
2018 | 1.46B | -1.69% |
2017 | 1.48B | -1131.72% |
The current Enterprise Value of ADC Therapeutics SA (ADCT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
419.33M
5-year avg
965.34M
10-year avg
952.82M
ADC Therapeutics SA’s Enterprise Value is greater than Passage Bio, Inc. (33.56M), greater than Black Diamond Therapeutics, Inc. (123.50M), greater than TCR2 Therapeutics Inc. (79.12M), less than Harpoon Therapeutics, Inc. (861.85M), greater than Alector, Inc. (185.51M), greater than Century Therapeutics, Inc. (88.73M), greater than Homology Medicines, Inc. (-103303255.00), greater than Generation Bio Co. (145.59M), less than Stoke Therapeutics, Inc. (467.23M), less than Ultragenyx Pharmaceutical Inc. (3.93B), less than Crinetics Pharmaceuticals, Inc. (4.74B), less than Arvinas, Inc. (1.15B), less than Revolution Medicines, Inc. (7.90B), less than Kura Oncology, Inc. (662.36M), less than Akero Therapeutics, Inc. (1.70B), less than Avidity Biosciences, Inc. (3.41B), less than Protagonist Therapeutics, Inc. (2.30B), less than Design Therapeutics, Inc. (323.81M), greater than ALX Oncology Holdings Inc. (92.36M), greater than Aadi Bioscience, Inc. (40.90M), greater than AlloVir, Inc. (-64850850.00),
Company | Enterprise Value | Market cap |
---|---|---|
33.56M | $40.03M | |
123.50M | $123.92M | |
79.12M | $58.11M | |
861.85M | $865.08M | |
185.51M | $188.03M | |
88.73M | $86.73M | |
-103303255.00 | $3.02M | |
145.59M | $73.47M | |
467.23M | $614.95M | |
3.93B | $4.05B | |
4.74B | $5.00B | |
1.15B | $1.24B | |
7.90B | $8.01B | |
662.36M | $695.21M | |
1.70B | $1.98B | |
3.41B | $3.77B | |
2.30B | $2.42B | |
323.81M | $351.62M | |
92.36M | $98.63M | |
40.90M | $70.49M | |
-64850850.00 | $52.01M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ADC Therapeutics SA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ADC Therapeutics SA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is ADC Therapeutics SA's Enterprise Value?
What is the highest Enterprise Value for ADC Therapeutics SA (ADCT)?
What is the 3-year average Enterprise Value for ADC Therapeutics SA (ADCT)?
What is the 5-year average Enterprise Value for ADC Therapeutics SA (ADCT)?
How does the current Enterprise Value for ADC Therapeutics SA (ADCT) compare to its historical average?